Alpha Cognition Inc. · NASDAQ:ACOG
Alpha Cognition — Investor Presentation (February 2023)
21 slides from Alpha Cognition's investor presentation, February 2023
Slide 1: Corporate Presentation
Corporate Presentation Bringing hope to people living with Neurodegenerative Diseases COPYRIGHT 2021 ALPHA COGNITION, INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this present
Slide 3: Pre-NDA Biopharmaceutical Company Focused on Neurodegenerative Diseases
Pre-NDA Biopharmaceutical Company Focused on Neurodegenerative Diseases ALPHA 1062 – Best-In-Class Treatment Potential • Large US $5.5B, 11M Rx market characterized by high drug dissatisfaction and discontinuation1 • Oral therapy uniquely designed to reduce side effects and improve long term patient
Slide 4: Alpha Cognition Value Creating Pipeline
Alpha Cognition Value Creating Pipeline Phase 3 Indication Preclinical Phase 1 Phase 2 /Pivotal Status / Upcoming Milestones ALPHA-1062 Mild-to-Moderate Alzheimer’s Disease Positive Pivotal BABE Top-line Results (AD) NDA filing June/July 2023 Additive, but not required for approval RESOLVE AD Patien
Slide 5: Alzheimer's Disease Overview
Alzheimer’s Disease Overview Alzheimer’s Disease (AD) is a progressive neurodegenerative disease for which there is no cure AD is characterized by loss of cholinergic neurons in the brain Decreased acetylcholine levels and loss of receptors negatively impacts learning, memory, and function AD Impact
Slide 6: ALPHA-1062: A Uniquely Designed Prodrug of Galantamine
ALPHA-1062: A Uniquely Designed Prodrug of Galantamine Potential best-in-class treatment designed to optimize efficacious dose, minimize treatment-limiting side-effects and improve long-term outcomes The formation of the benzoyl ester eliminates AChE inhibition; the gluconate salt increases solubili
Slide 7: Galantamine Enhances Acetylcholine Levels and Modulates Nicotinic Receptor Sensitivity
Galantamine Enhances Acetylcholine Levels and Modulates Nicotinic Receptor Sensitivity Decreased acetylcholine levels and loss of nicotinic acetylcholine receptors (nAChR) negatively impacts learning, memory, and function B Current therapeutics1 increase acetylcholine levels by inhibiting acetylchol
Slide 8: Galantamine, the Active Moiety of ALPHA-1062, Demonstrates Strongest Effect on Mortality and Cognitive Decline
Galantamine, the Active Moiety of ALPHA-1062, Demonstrates Strongest Effect on Mortality and Cognitive Decline • In an April 2021 Neurology publication, 39,196 Alzheimer/Mixed Dementia patients (Swedish Dementia Registry) were evaluated between 2007-2017 with a 5yr average follow-up • Galantamine wa
Slide 9: Pivotal Trial Results Provide Data That Support NDA Filing
Pivotal Trial Results Provide Data That Support NDA Filing BioEquivalence Study vs. Immediate Release Bioequivalence Study vs. Extended Release ALPHA-1062 Gal HBr % to ALPHA- Sufficient PK Delayed Immediate Reference 1062 Gal HBr % to Sufficient Data for NDA Parameter Release 5mg Release 4mg Drug PK
Slide 10: Studies Have Demonstrated Improved Gastrointestinal Side Effect Profile
Studies Have Demonstrated Improved Gastrointestinal Side Effect Profile* < 1% GI side-effects with oral formulations of ALPHA-1062 (Delayed Release and Sublingual Tablets, n=106) Diarrhea Nausea & Vomiting 40 37.8 35 % of Subjects Reporting GI Episode 30 25 20.0 20 15 8 9 10 5 0.9 <1 0 0 ALPHA-1062
Slide 11: ALPHA-1062: Offers Potential Best-In-Class Profile Versus Approved AChEIs
ALPHA-1062: Offers Potential Best-In-Class Profile Versus Approved AChEIs ALPHA-1062 Donepezil Galantamine Donepezil Patch Time to Therapeutic Dose Low titration to therapeutic dose & Symptom for faster onset of improvement Improvement Reduced GI side-effects (diarrhea, GI Safety Profile nausea, vom
Slide 12: Multiple AD Launches Have Achieved Blockbuster Status
Multiple AD Launches Have Achieved Blockbuster Status Peak Sales (in B) $2.6 $1.8 $1.25 $0.650 $0.270 $0.250 • Large US $5.5B, 11M Rx market characterized by high drug dissatisfaction and discontinuation Namenda Namenda XR Namzaric Aricept Exelon Razadyne • Multiple successful launches into the AD s
Slide 13: NAMZARIC 505(b)(2) Treatment Delivers +$250M In Sales
Despite No Differentiation And No Promotion, NAMZARIC, 505(b)(2) Treatment For Moderate-to-Severe Alzheimer’s Delivers +$250M In Sales NAMZARIC Sales by Year ($M) $300 • NAMZARIC provides base case for sales for a new $267 symptomatic entrant into the Alzheimer’s market $246 $250 $219 $203 • 505(b)(
Slide 14: ALPHA-1062 Has a Significant Market Opportunity in Alzheimer's Disease
ALPHA-1062 Has a Significant Market Opportunity in Alzheimer's Disease Alzheimer’s Disease Treatable Alzheimer’s Disease Treated Patients Reaching Patient Market1 Each Line of Therapy 2 6.3M Total Available AD Patients Strategic MCI and Dementia Opportunity 3.4M Addressable Patients ~1.9M Mild to Mo
Slide 15: ALPHA-1062 Alzheimer's Dementia Opportunity
ALPHA-1062 Alzheimer's Dementia Opportunity De-risked Large but ALPHA-1062 Clinical Development Near-term Dissatisfied Market Potential Program Milestones $5.5B Market Size Reduced Adverse Positive NDA Submission Event Profile Bioequivalence June/July 2023 30% Discontinue study results treatment at
Slide 16: Pipeline: ALPHA-1062 + Memantine Will Expand Usage into Moderate-to-Severe Alzheimer's Dementia
Pipeline: ALPHA-1062 + Memantine Will Expand Usage into Moderate-to-Severe Alzheimer’s Dementia Mild ALPHA-1062 • Memantine indicated for moderate-to-severe Alzheimer’s dementia • Formulation work to continue in 2023 • 505(b)2 regulatory path for approval of combination product ALPHA-1062 – Preceden
Slide 17: Pipeline: ALPHA-1062 Intranasal Delivery Offers Potential Benefits To Large TBI Market
Pipeline: ALPHA-1062 Intranasal Delivery Offers Potential Benefits To Large TBI Market With No Approved Treatment Preclinical Results1 Why ALPHA-1062 Intranasal? • Statistically significantly improved motor and • Active Metabolite demonstrated to: sensory functional recovery and cognitive – Reduce n
Slide 18: Potential Catalysts and Upcoming Events
Potential Catalysts and Upcoming Events Pre-IND meeting for ALPHA-1062 Intranasal in mTBI (Q2) NDA submission for ALPHA-1062 in AD (July 2023) 2023 IND submission for ALPHA-1062 Intranasal for mTBI (Q4) Initiation of mTBI PH2 study (Q4) – contingent on TBI financing ALPHA-1062 in AD product approval
Slide 19: Leadership Has Impressive Track Record for Successful New Drug Development and Commercialization
Leadership Has Impressive Track Record for Successful New Drug Development and Commercialization Michael McFadden Denis Kay Lauren D’Angelo, MBA Don Kalkofen Chief Executive Officer Chief Science Officer Chief Commercial Officer Chief Financial Officer COPYRIGHT 2021 ALPHA COGNITION, INC. 19
Slide 20: Share Structure as of Sept 30, 2022
Share Structure as of Sept 30, 2022 ACOG.V, ACOGF Share Price (as of Jan 26, 2023) $0.39 CAD ($0.29 US) Market Cap $26M CAD ($19.4M US) Issued and Outstanding* % (Diluted) Common Shares 61,023,450 56.79% Warrants 9,602,500 8.94% Class A Restricted Shares 7,000,000 6.51% Class B Preferred Series A Sh
Slide 21: Don Kalkofen info@alphacognition.com
Don Kalkofen info@alphacognition.com COPYRIGHT 2021 ALPHA COGNITION, INC. 21
Alpha Cognition — Investor Presentation (February 2023) on 6ix